Action VCKAU VICKERS VANTAGE CORP. I
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Communiqués Vickers Vantage Corp. I Nasdaq

Actions

VCKAU

KYG9440B1234

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. and Vickers Vantage Corp. I Announce the Closing of their Previously Announced Business Combination
AQ
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics Inc. Debuts on Nasdaq Under Ticker 'SCLX'
AQ
VICKERS VANTAGE CORP. I : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
VICKERS VANTAGE CORP. I Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Scilex Holding Company a Sorrento Company and Vickers Vantage Corp. I Announce Effectiveness of Registration Statement on Form S-4, Date of Vickers Vantage Extraordinary General Meeting to Approve Proposed Business Combination
AQ
Vickers Vantage I : Merger Agreement - Form 8-K
PU
VICKERS VANTAGE CORP. I : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
VICKERS VANTAGE CORP. I : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 5.4%, Next Generation Triple Strength Formulation of ZTlido, For the Treatment of Acute Low Back Pain
AQ
Scilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement with CH Trading Group LLC to Expand Commercialization of ZTlido
AQ
Scilex Holding Company, a Sorrento Company, Announces Expanding Coverage to 30 Million Lives And Will Continue To Work To Access An Additional 20 Million Lives With One Of The Largest National Pharmacy Benefit Managers
AQ
VICKERS VANTAGE CORP. I Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Vickers Vantage I : Announces Shareholder Approval of Extension of Deadline to Complete Business Combination – Form 8-K
PU
Vickers Vantage I : Announces Shareholder Approval of Extension of Deadline to Complete Business Combination - Form 8-K
PU
VICKERS VANTAGE CORP. I : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba
AQ
Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.
AQ
Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured Notes
AQ
VICKERS VANTAGE CORP. I : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Scilex Holding Company, a Sorrento Company, and Vickers Vantage Corp. I announced today the filing of a Registration Statement on Form S-4 with the Securities and Exchange Commission
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action VCKA
  4. Action VCKAU
  5. Actualités Vickers Vantage Corp. I
  6. Communiqués